Erlotinib Not Yet Recruiting Phase 4 Trials for Adenocarcinoma of the Lung Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02399566Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma